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with in the near future  [3] . DME is a sight-threatening 
complication which needs a timely treatment; more than 
50% of incorrectly treated patients lose several lines of 
visual acuity (VA) within a few years  [4] .
 For many years now grid and focal laser photocoagula-
tion have been considered the standard therapy for the 
treatment of visual impairment due to DME  [5] ; however, 
laser therapy acts upon vision stabilization with the de-
struction of retinal tissue and does not control all cases of 
DME. In the Early Treatment Diabetic Retinopathy Study 
(ETDRS), patients with vision loss due to DME who were 
immediately treated with laser therapy had a reduction by 
half of the risk of losing 15 letters of VA compared to 
those receiving a deferred treatment  [6] . More recent 
studies reported a VA improvement of only 0.9 letters  [7] 
and 3 letters  [8] for patients treated with laser monother-
apy according to ETDRS criteria; however, in the Dia-
betic Retinopathy Clinical Research Network trial (DRCR.
net)  [9] a small group of laser-treated patients (21%) 
achieved a gain of 15 letters in VA at 2 years, suggesting 
a delayed benefit related to laser therapy. Therefore, even 
if trying to prevent further vision loss is important, today 
therapies that could restore VA in patients with visual 
impairment related to DME are certainly required.
 With the development of intravitreal pharmacothera-
pies such as antivascular endothelium growth factor (an-
ti-VEGF) agents and steroids, new strategies in the man-
agement of this complex disease have been recommend-
ed. Compared to laser procedure, the intravitreal approach 
has the great advantage of potentially promoting visual 
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 Abstract 
 Diabetic macular edema is considered the most important 
factor related to visual impairment in patients with diabet-
ic retinopathy. Together with the use of grid and focal laser 
photocoagulation, today the intravitreal administration of 
pharmacotherapies represents the standard of care for the 
treatment of this complication: anti-vascular endothelium 
growth factor agents and steroids are the drugs currently 
used for this aim. Differently from laser therapy, which pre-
vents visual deterioration, the intravitreal approach allows 
the promotion of visual recovery. However, the intravitreal 
injections require to be repeated with high frequency, and 
this carries the risk of drug- and procedure-related adverse 
 effects.  © 2014 S. Karger AG, Basel 
 Introduction 
 Diabetic macular edema (DME) is the leading cause of 
visual impairment in people with diabetes mellitus  [1] . 
The prevalence of diabetes is growing quickly in the pop-
ulation  [2] , so that the development of DME in working-
age people will represent an increasing problem to deal 
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recovery; however, this new strategy usually requires re-
peated interventions, with a higher risk of drug- or pro-
cedure-related adverse effects.
 VEGF is a homodimeric protein which acts by stimu-
lating the proliferation of vascular endothelial cells and 
inducing an increase in vascular permeability  [10] . Sev-
eral studies have highlighted a central role of this factor in 
promoting DME development  [11, 12] ; from these studies 
came the idea to highlight therapeutic agents in order to 
contrast the VEGF functions. The main anti-VEGF agents 
studied for the treatment of DME are ranibizumab (Lu-
centis ® ), bevacizumab (Avastin ® ) and pegaptanib sodium 
(Macugen ® ); in addition, recent results have also reported 
an interesting role of aflibercept (VEGF Trap-Eye, Eylea). 
The efficacy and safety of these drugs have been carefully 
compared to placebo and to laser photocoagulation, show-
ing favorable results  [13–23] . In particular, ranibizumab 
(Lucentis; Novartis Pharma AG, Basel, Switzerland and 
Genentech Inc., San Francisco, Calif., USA) was recently 
approved by the European Medicines Agency for the treat-
ment of visual impairment due to DME  [24] .
 The use of steroids for the treatment of DME has been 
studied for many years because of their strong anti-in-
flammatory and anti-edema properties. Several studies 
clearly reported the effect of steroids in reducing VEGF 
expression, leukostasis and inflammatory cytokine pro-
duction  [25, 26] . Different classes of intravitreal steroids 
are available today; they differ in biological properties 
and duration of action ( table 1 ). Steroids administered in-
travitreally stabilize VA and reduce DME, but they are 
also associated with frequent side effects, the most fre-
quent (reported from all types of steroids) being an in-
crease in intraocular pressure (IOP) and cataract progres-
sion. For this reason they are generally used in patients 
affected by persistent or refractory DME, especially in 
pseudophakic eyes.
 In this review we focus on the more relevant evidence 
for the use of steroids in patients with DME, reporting 
their efficacy for the treatment of this complex disease. 
Three different types of intravitreal steroid are now avail-
able: triamcinolone acetonide, fluocinolone acetonide 
and dexamethasone. Fluocinolone acetonide and dexa-
methasone are contained in sustained-release drug deliv-
ery devices that, inserted into the vitreous, allow the re-
lease of the steroid with a longer duration of action, re-
ducing the number of intravitreal injections.
 Clinical Trial Evidence for Intravitreal Triamcinolone 
Acetonide in DME 
 Intravitreal triamcinolone acetonide (IVTA) is com-
mercially available today in suspension form with the 
names, among others, Trivaris (Allergan, Irvine, Calif., 
USA), Kenacort (Bristol-Myers-Squibb, Melbourne, Vic., 
Australia) and Kenalog (Bristol-Myers-Squibb, Prince-
ton, N.Y., USA). IVTA was first reported for the treat-
ment of age-related macular degeneration  [27] ; some 
years later, it was also used for the treatment of DME  [28] .
 Since 1991 IVTA has been used in many small case se-
ries and randomized clinical trials (RCTs)  [29–33] ; differ-
ent IVTA injection strategies, administered with a single 
injection (4 or 20 mg)  [29–32] or with multiple injections 
(4 mg) for up to 2 years  [33] , have been compared with 
observation. These studies were later evaluated in a Co-
chrane review, the data of which showed some favorable 
results, although IVTA was unfortunately associated with 
an increased risk of side effects. In particular, the results 
showed a 1-line improvement of VA at 3 months in an 
eye receiving a single IVTA injection, but this was not 
maintained at 6 months  [32] . However, in the group re-
ceiving multiple injections, an IVTA treatment effect was 
still present at the 2-year follow-up  [33] . It has been as-
sumed that with the strategy of a single injection there is 
a gradual reduction in the drug concentration in the eye, 
leading to a drop-off effect, while the possibility to receive 
 Table 1.  Intravitreal steroids under investigation for the treatment of DME
Drug Dosage Biological features Surgical procedure Duration of action
Triamcinolone acetonide 1 or 4 mg Biodegradable Intravitreal injection 2–4 months (depending on the dosage)
Fluocinolone acetonide (Retisert) 0.59 mg Nonbiodegradable Surgical incision and suture 3 years
Fluocinolone acetonide (Iluvien) 250 μg (0.2 or
0.5 μg/day)
Nonbiodegradable Prefilled, single-use, 25-gauge needle 3 years
DEX implant (Ozurdex) 0.7 mg Biodegradable Prefilled, single-use, 22-gauge applicator 4–6 months
Modified from Bandello et al. [56].
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a reinjection of IVTA, in the case of a decline in VA, pro-
motes a more sustained effect.
 An earlier RCT evaluated the effect of IVTA (4 mg) for 
the treatment of refractory DME  [34] . In a 2-year follow-
up period, IVTA showed a best-corrected VA (BCVA) 
improvement in 56% of the treated eyes (with a mean 
number of 2.6 injections) compared to 26% of the control 
group; it also revealed an increased risk of cataract pro-
gression (54% of treated patients vs. 0% of controls) and 
a rise in IOP, requiring topical medication (44 vs. 3%, re-
spectively). Moreover, the effects of IVTA in refractory 
DME have been investigated for 5 years  [35] . All eyes, 
including those initially randomized to the placebo group, 
were switched to receive IVTA. The results showed a gain 
of 5 or more letters in 42% of the treated eyes compared 
to 32% of eyes initially treated with placebo and then with 
IVTA. Therefore, the majority of eyes that initially im-
proved with IVTA maintained their gain after 5 years and 
some of the eyes initially not treated had a visual improve-
ment, suggesting the usefulness of IVTA in carefully se-
lected cases with impaired vision caused by advanced 
DME that do not respond to other interventions.
 The efficacy of IVTA for the treatment of DME was 
compared to macular laser photocoagulation. Although 
an early RCT showed better results in terms of VA gain in 
patients treated with IVTA  [36] , the 3-year results of the-
DRCR.net  [38] did not demonstrate a long-term advan-
tage of IVTA compared to macular laser photocoagula-
tion. The DRCR.net compared the efficacy and safety of 
preservative-free IVTA to focal/grid laser photocoagula-
tion (considered the standard of care) for the treatment of 
DME in a follow-up period of 2 years, which was then 
extended to 3 years  [37, 38] . Patients were randomized to 
3 arms to receive focal/grid laser photocoagulation, IVTA 
1 mg or IVTA 4 mg, respectively. Even if a greater gain in 
BCVA was reported in the IVTA 4-mg arm at 4 months, 
nonsignificant differences in BCVA were noticed among 
the 3 groups after the first year. However, at the 2-year end 
point, mean BCVA was better in the laser group, and this 
result was also confirmed by the central retinal thickness 
(CRT) measurements from optical coherence tomogra-
phy. These data were confirmed in the expanded 3-year 
follow-up: the laser group presented a BCVA improve-
ment of +5 letters while no BCVA change was noticed in 
the 2 IVTA groups (+0 letters). With regard to the side 
effects, at the third year an IOP increase of  ≥ 10 mm Hg 
was reported in 4, 18 and 33% of the 3 arms, respectively, 
with an increased probability of cataract surgery in 31, 46 
and 83%. Therefore, the authors concluded that the IVTA 
approach did not reveal long-term benefits in the treat-
ment of DME compared to laser photocoagulation. An 
additional analysis was performed on the participants of 
this study in order to evaluate the effects of IVTA injection 
compared to laser therapy on the progression of diabetic 
retinopathy (DR) at 3 years  [39] . Data showed a reduction 
in the risk of DR progression in patients treated with 
IVTA 4 mg compared to the IVTA 1 mg and laser groups 
(21 vs. 29 vs. 31%, respectively). Nevertheless, the use of 
IVTA as a therapeutic strategy to reduce or slow down the 
progression of DR was not suggested by the authors.
 Later, the DRCR.net performed a large RCT in order to 
evaluate the effects of two different intravitreal agents, tri-
amcinolone acetonide (steroid) and ranibizumab (anti-
VEGF agent) for the treatment of center-involving DME. 
In the trial the effectiveness of different combined strate-
gies, including an intravitreal drug associated with grid/
focal laser photocoagulation, were compared to laser 
monotherapy during a follow-up of 1 year, which was then 
extended to 2 years  [8, 9] . The enrolled patients were ran-
domly assigned to 4 arms: sham injection plus laser, 0.5 mg 
of intravitreal ranibizumab (IVR) plus prompt laser, 
0.5 mg IVR plus deferred laser and 4 mg IVTA plus prompt 
laser. At the first year end point  [8] data showed a greater 
benefit in terms of BCVA gain in the groups with IVR plus 
prompt or deferred laser compared to the arms with IVTA 
plus laser and laser alone; the 3 study groups evaluating 
IVTA or IVR plus laser also revealed similar results in CRT 
measurements, with a greater reduction in CRT compared 
to the group with laser alone. At the extended 2-year fol-
low-up the results were consistent with those published 
after the first year  [9] . Compared to the group with laser 
alone, the mean change in BCVA was +3.7 letters better in 
the group with IVR plus prompt laser, +5.8 letters greater 
in the group with IVR plus deferred laser and –1.5 letters 
worse in the group with IVTA plus prompt laser. The ste-
roidal approach affirmed a good security profile despite a 
greater incidence of cataract, which in phakic patients lim-
ited the visual gain and required surgery in 55% of cases 
versus 12% in the IVR group. In contrast, in the subgroup 
of pseudophakic eyes, the IVTA plus laser strategy pro-
vided greater benefits than laser alone, and it was not infe-
rior to the IVR plus laser option. However, an increased 
risk of IOP rise was noticed in all groups treated with the 
steroid (38% in IVTA plus laser vs. 5% in IVR plus laser). 
Therefore, the authors indicated the IVR injection as an 
efficient treatment for DME with macular involvement; 
on the other hand, the IVTA strategy could probably rep-
resent an alternative option in pseudophakic patients.
 Another RCT promoted by the DRCR.net evaluated 
the effects of ranibizumab and triamcinolone acetonide 
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in eyes previously treated with focal/grid laser for DME 
and panretinal photocoagulation for DR  [40] . In this 
study, the addition of 1 IVTA or 2 IVR injections in eyes 
formerly treated with laser of the periphery and posterior 
pole was associated with VA improvement and decreased 
macular edema at 14 weeks, but not at 56 weeks.
 Today, indications for the use of IVTA for DME have 
not been established. Triamcinolone is available in  Europe 
for some other therapeutic indications (intra-articular 
use) and so the intravitreal administration must be con-
sidered off-label. Nevertheless, the role of IVTA alone or 
as an adjunct to laser could be carefully considered in se-
lected cases of visual loss due to persistent or refractory 
DME, especially in pseudophakic eyes ( table 2 ).
 Clinical Trial Evidence for Intravitreal Fluocinolone 
Acetonide in DME 
 Fluocinolone acetonide is an attractive drug because of 
its potency, solubility and lipophilicity. It has been for-
mulated into two different types of sustained drug deliv-
ery devices: Retisert ® (Bausch & Lomb, Rochester, N.Y., 
USA) and Iluvien ® (Alimera Sciences, Atlanta, Ga., 
USA). These innovative sustained-release implants have 
already been tested and might have some potential in the 
treatment of persistent DME.
 Retisert is a nonbiodegradable device containing 0.59 
mg of fluocinolone acetonide, which is inserted into the 
vitreous through a pars plana incision and is well devel-
oped to release sustained levels of the drug for almost 
30 months. After the surgical implantation of the de-
vice, the steroid is released into the eye at an initial rate 
of about 0.6 μg/day and then progressively decreased to 
a steady rate of nearly 0.3–0.4 μg/day after the first 
month. Retisert has been approved as a validated treat-
ment option of chronic, noninfectious posterior uveitis 
 [41] but not for DME as yet. However, a large multi-
center RCT has recently tested the efficacy and safety of 
Retisert for the treatment of persistent or recurrent 
DME; the study design considered a 4-year follow-up, 
and data at 3 years have already been published  [42] . In 
detail, patients were randomized to 2 arms: Retisert im-
plant (0.59 mg) or observation/additional laser photoco-
 Table 2.  Main clinical trials that evaluated the use of steroids for the treatment of DME
Study Name of steroid Number 
of eyes
Study design Follow-up Major conclusions
Gillies 
[35], 2009
Triamcinolone 
acetonide
69→44 IVTA (4 mg) vs. sham; 
laser if appropriate
5 years Final VA comparable; delayed intervention 
did not compromise the possibility to 
respond (advanced DME)
DRCR.net 
[37], 2009
Triamcinolone 
acetonide
840→306 IVTA (1 or 4 mg) vs. 
laser
3 years Laser: +5 letters; IVTA arms: 0 letters; no real 
long-term advantage of IVTA despite laser
DRCR.net 
[39], 2011
Triamcinolone 
acetonide
854 IVR (0.5 mg) + prompt 
or deferred laser vs. 
IVTA (4 mg) + prompt 
laser vs. laser
2 years Compared to laser, IVR + laser groups 
improved VA; IVTA group did not; in 
pseudophakic eyes IVTA made a VA 
improvement equal to IVR
Pearson 
[41], 2011
Fluocinolone 
acetonide (Retisert)
196 Retisert insert (0.59 mg) 
vs. laser or observation
3 years Better VA and CRT improvement of IVFA 
group at 2 years, but not at 3 years; high 
incidence of cataract and glaucoma
Campochiaro 
[44], 2012
Fluocinolone 
acetonide (Iluvien)
953→672 Iluvien insert (0.2 or 0.5 
μg/day) vs. sham
3 years Compared to sham, significant improvement 
in VA of IVFA groups; more benefit in patients 
with DME duration ≥3 years; frequent 
 cataracts, but good result after surgery
Haller 
[49], 2010
Dexamethasone 
(Ozurdex)
171 DEX implant (700 or 
350 μg) vs. sham
6 months VA improvement ≥10 letters in more treated 
eyes, especially the 700-μg group; IOP 
increase effectively treated with topical 
medication
Modified from Stewart [57].
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agulation (considered the standard of care). Data re-
vealed a BCVA gain of 3 or more lines in 16.8% of im-
planted eyes after 6 months, 16.4% after 1 year, 31.8% 
after 2 years, and 31.1% after 3 years compared to 1.4, 
8.1, 9.35 and 20% in the standard of care group at the 
same time points. Compared to the standard of care 
group, a higher rate of reduction of CRT at each time 
point was also noticed in the treated group. Neverthe-
less, the results also showed a higher frequency of sec-
ondary effects related to intravitreal fluocinolone ace-
tonide (IVFA) treatment: at the end of the 4-year follow-
up cataract extraction was needed in 91% of phakic eyes, 
and 33.8% of treated eyes required surgical management 
of IOP elevation ( ≥ 30 mm Hg, which was observed in 
61.4% of all treated eyes at any follow-up time). Despite 
the high incidence of complications, the authors sug-
gested the IVFA implant as a possible approach in pa-
tients with recurrent or persistent DME.
 Iluvien is a smaller, long-lasting nonbiodegradable in-
sert containing 250 μg of fluocinolone acetonide. It is in-
jected into the vitreous through a 25-gauge needle and 
engineered to release 0.5 or 0.2 μg/day of the active prin-
ciple  [43] . The efficacy of Iluvien insert for the treatment 
of DME resistant to laser was evaluated in recent RCTs, 
with a 3-year follow-up period (FAME studies)  [44, 45] . 
Patients with persistent DME and at least one prior laser 
treatment were randomly assigned to 3 arms: IVFA 
0.2 μg/day (low dose), IVFA 0.5 μg/day (high dose) or 
sham injection. Data showed a BCVA improvement of 
15 or more letters in 28.7, 27.8 and 18.9% of the 3 groups, 
respectively, at both 24 and 36 months. Retreatment was 
possible after 12 months and it was performed in 25% of 
patients (with a mean number of 4 inserts over 3 years). 
Moreover, about 40% of patients underwent rescue laser 
treatment. In addition, to evaluate whether the duration 
of DME could play a role in determining the response to 
therapy, a further analysis has been developed which 
clearly revealed that the response to IVFA was better in 
the subgroup of patients with long-lasting DME. In par-
ticular, for patients with a mean disease duration of 3 or 
more years, the number of significant responses (BCVA 
gain of 15 or more letters) was significantly higher in the 
group treated with the steroid implant. In contrast, the 
number of patients with a mean duration of DME of less 
than 3 years who presented an adequate BCVA improve-
ment (15 or more letters) was not significant  [45] . Un-
fortunately, side effects were frequent; almost all phakic 
eyes required cataract extraction and the rate of glauco-
ma needing surgical intervention was 4.8 and 8.1% in the 
low- and high-dose groups, respectively. Despite the 
high frequency of cataract and glaucoma, the authors 
concluded that the IVFA implant could be a valuable 
therapeutic option in eyes with chronic DME that were 
refractory to previous treatments, owing to the high rate 
of response.
 Because of its adverse events, IVFA has failed to re-
ceive the Food and Drug Administration (FDA) approv-
al in the USA. Nevertheless, Iluvien is approved in sev-
eral European countries for the treatment of refractory/
persistent DME ( table 2 ).
 Clinical Trial Evidence for Dexamethasone 
Intravitreal Implant in DME 
 Dexamethasone intravitreal implant (DEX implant, 
Ozurdex ® ; Allergan) is a biodegradable device contain-
ing 0.7 mg of preservative-free dexamethasone. The de-
vice is injected into the vitreous through a prefilled, sin-
gle-use, 22-gauge applicator, and it was engineered to de-
liver the drug with slow-release kinetics. DEX was first 
used together with antibiotics for the medical treatment 
of bacterial endophthalmitis; today the DEX sustained-
delivery system has been approved and validated by the 
FDA in the USA and by the European Union (EU) for the 
treatment of patients with chronic noninfectious poste-
rior uveitis  [46] and macular edema due to retinal vein 
occlusion  [47] .
 The efficacy and safety of the DEX implant has been 
evaluated in patients with DME  [48–55] . First, in a 
6-month RCT, patients with persistent macula edema 
secondary to different pathologies, including DME, ret-
inal vein occlusion, Irvine-Gass syndrome and uveitis, 
received the DEX implant (700 or 350 μg) or a sham in-
jection  [49] . At the 3-month follow-up data showed a 
BCVA gain of 10 or more letters in 35% (700 μg) and 24% 
(350 μg) of the DEX implant arms, respectively, com-
pared to 13% of the sham group. An IOP increase of 
10 mm Hg or higher was detected in 11% of both of the 
DEX implant groups compared to 2% of the control 
group.
 A further analysis of this study evaluated the effects of 
dexamethasone in the specific subgroup of patients af-
fected by DME, revealing a potential role of the DEX im-
plant for the treatment of persistent DME  [50] . In par-
ticular, at the third month a BCVA improvement of 10 or 
more letters was observed in 33.3, 21.1 and 12.3% of the 
3 groups (DEX 700 μg, DEX 350 μg and sham group), re-
spectively. Furthermore, the visual gain was maintained 
until the 6-month follow-up in 30, 19 and 23% of the 3 
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groups, respectively. A great improvement in CRT and 
fluorescein leakage was also noticed in the treated eyes. 
Regarding the side effects, an IOP increase reaching val-
ues  ≥ 25 mm Hg was detected in 12.7, 7.5 and 0% of the 3 
groups, respectively, but it was effectively treated with 
topical medications.
 The efficacy of the DEX implant has also been evalu-
ated in eyes affected by DME refractory to pars plana vit-
rectomy, revealing a significant improvement in BCVA 
measurements, CRT values and vascular leakage after 26 
weeks  [51] . In this study the DEX implant was injected 
into vitrectomized eyes, revealing a mean gain in BCVA 
of 6 and 3 letters and a mean reduction in CRT of 156 and 
39 μm at weeks 8 and 26, respectively, showing a sus-
tained treatment effect despite previous surgery.
 A further 2 RCTs assessed the efficacy and safety of the 
DEX implant in small study populations affected by per-
sistent DME  [52, 53] . These studies reported similar re-
sults, showing an effect of the DEX implant in producing 
an improvement in BCVA and CRT measurements from 
the first and third day after injection until the fourth and 
third month, respectively. Moreover, a recent trial inves-
tigated the use of the DEX implant in patients with chron-
ic DME nonresponsive to intravitreal anti-VEGF treat-
ment (3 consecutive monthly injections)  [54] . As with 
previous results, this study also revealed the efficacy of the 
DEX implant, with an improvement of BCVA and CRT 
values until 4 months. A slight increase in IOP was no-
ticed in all recruited patients, which did not require surgi-
cal intervention.
 However, a recent trial compared a DEX implant plus 
laser combination therapy to laser alone for the treatment 
of diffuse DME  [55] . Although a greater improvement of 
BCVA with a gain of 10 or more letters was seen from the 
first to the ninth month in the combination group, this 
difference was not confirmed at 12 months.
 Recently, a phase III, multicenter, masked, random-
ized, sham-controlled trial evaluated the safety and effi-
cacy of 700 and 350 μg of the dexamethasone posterior 
segment drug delivery system (DEX PS DDS ® ) applica-
tor system in the treatment of DME. More than 1,000 
patients were randomized to each of the 3 arms of the 
study: DEX 700 μg, DEX 350 μg or sham delivered by 
sustained-release implant. Retreatments were delivered 
every 6 months, if necessary. According to the results, the 
percentage of patients with a gain of 15 or more letters 
was significantly greater in the DEX-treated patients 
than in the sham-treated group at 3 years, which was the 
primary end point. Furthermore, treatment benefit was 
observed with a mean of 4.1 injections over the 36 months 
of follow-up. The safety profile was as good as or better 
than that in other studies; IOP elevations rarely required 
treatment and there was no evidence of increased sys-
temic adverse events or risk of arterial thromboembolic 
events after repeated treatment [Boyer D.S., MEAD 
Study – data presented at AAO meeting, New Orleans, 
2013].
 The DEX implant has not yet received FDA and EU 
approval for its use in DME. Nevertheless, it should be 
considered as an effective therapeutic option in patients 
with recurrent or persistent DME, especially in pseudo-
phakic eyes ( table 2 ).
 Conclusions 
 Nowadays, the combination of intravitreal anti-
VEGF agents and macular laser photocoagulation is 
considered the standard of care for the treatment of pa-
tients with DME. However, intravitreal steroid injec-
tions or implants showed favorable results as a therapeu-
tic option for the management of DME, especially as an 
additional choice in pseudophakic patients and in pa-
tients previously treated with anti-VEGF agents, laser 
and vitrectomy with poor results. The major problem 
with steroid use is related to the high rates of intraocular 
complications.
 Several investigations have tried to reveal the role of 
combination therapy as a valuable, long-lasting option in 
order to improve the patient’s response and reduce the 
frequency of retreatment. For this purpose a practical 
therapeutic algorithm for the treatment of DME has re-
cently been proposed  [56] .
 To conclude, we expect to assist in a continuous incre-
ment in the use of steroids for selected patients with DME, 
especially as an alternative strategy for eyes in which laser 
and anti-VEGF agents have failed. 
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